Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115- Proposed Biosimilar to Ustekinumab
Shots:
- Meiji and Dong-A ST to receive an upfront & will be eligible to receive development & sales milestones along with profit share. The companies collaborated to commercialize DMB-3115 proposed biosimilar to ustekinumab for the treatment of inflammatory diseases such as PsO- CD & UC
- Intas to get exclusive license rights to commercialize DMB-3115 globally- Ex-Japan- Korea & Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its WW affiliates
- DMB-3115 is being evaluated in a P-III multi-regional clinical trial to treat patients with PsO in the EU & US
| Ref: Meiji | Image: Meiji
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
